Adia Labs Launches Turnkey Clinic Model for Chiropractic Practices with BoldMD 
Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era
A redesigned Weight Watchers experience pairs GLP-1 prescriptions with personalized nutrition, coaching, community support, and cutting-edge technology to help members...
Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era
A redesigned Weight Watchers experience pairs GLP-1 prescriptions with personalized nutrition, coaching, community support, and cutting-edge technology to help members...
Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan
Vivos Eyes High Growth Potential from Commercial Affiliation with Prominent Auburn Hills, Michigan Sleep Practice MISleep SolutionsLITTLETON, Colo., Dec. 16,...
Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan
Vivos Eyes High Growth Potential from Commercial Affiliation with Prominent Auburn Hills, Michigan Sleep Practice MISleep SolutionsLITTLETON, Colo., Dec. 16,...
Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan
Vivos Eyes High Growth Potential from Commercial Affiliation with Prominent Auburn Hills, Michigan Sleep Practice MISleep SolutionsLITTLETON, Colo., Dec. 16,...
Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
Vancouver, Canada, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
Vancouver, Canada, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
Vancouver, Canada, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer
Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full...
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer
Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full...
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer
Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full...
SRx Health Enters into Definitive Agreement to Acquire EMJX to Establish Next-Generation Digital Asset Treasury Operating System and Platform Led by Eric M. Jackson
Upon closing, Eric M. Jackson to Lead Combined Company as Chief Executive Officer and ChairmanNORTH PALM BEACH, Fla., Dec. 16,...
SRx Health Enters into Definitive Agreement to Acquire EMJX to Establish Next-Generation Digital Asset Treasury Operating System and Platform Led by Eric M. Jackson
Upon closing, Eric M. Jackson to Lead Combined Company as Chief Executive Officer and ChairmanNORTH PALM BEACH, Fla., Dec. 16,...
SRx Health Enters into Definitive Agreement to Acquire EMJX to Establish Next-Generation Digital Asset Treasury Operating System and Platform Led by Eric M. Jackson
Upon closing, Eric M. Jackson to Lead Combined Company as Chief Executive Officer and ChairmanNORTH PALM BEACH, Fla., Dec. 16,...
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
Appointment Enhances PolyPid’s Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application SubmissionPETACH TIKVA, Israel, Dec. 16, 2025...
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
Appointment Enhances PolyPid’s Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application SubmissionPETACH TIKVA, Israel, Dec. 16, 2025...
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
Appointment Enhances PolyPid’s Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application SubmissionPETACH TIKVA, Israel, Dec. 16, 2025...
December 2025 Letter to Shareholders
VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence...
December 2025 Letter to Shareholders
VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence...
December 2025 Letter to Shareholders
VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence...